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Abstract 
 
In contrast to recessive conditions with biallelic inheritance, identification of dominant 
(monoallelic) mutations for Mendelian disorders is more difficult, because of the abundance of 
benign heterozygous variants that act as massive background noise (typically, in a 400:1 
excess ratio). To reduce this overflow of false positives in Next-Generation Sequencing (NGS) 
screens, we developed DOMINO (https://wwwfbm.unil.ch/domino/), a tool assessing the 
likelihood for a gene to harbor dominant changes. Unlike commonly-used predictors of 
pathogenicity, DOMINO takes into consideration features that are the properties of genes, 
rather than of variants. It uses a machine-learning approach to extract discriminant information 
from a broad array of features (N=432), including: genomic data, intra- and interspecies 
conservation, gene expression, protein-protein interactions, protein structure, etc. DOMINO’s 
iterative architecture includes a training process on 985 genes with well-established 
inheritance patterns for Mendelian conditions, and repeated cross-validation that optimizes its 
discriminant power. When validated on 99 newly-discovered genes with pathogenic mutations, 
the algorithm displays an excellent final performance, with an area under the curve (AUC) of 
0.92. Furthermore, unsupervised analysis by DOMINO of real sets of NGS data from 
individuals with intellectual disability or epilepsy correctly recognizes known genes and 
predicts 9 new candidate genes, with very high confidence. In summary, DOMINO is a robust 
and reliable tool that can predict dominance of candidate genes with high sensitivity and 
specificity, making it a useful complement to any NGS pipeline dealing with the analysis of the 
morbid human genome. 
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By allowing the simultaneous identification of thousands of DNA variants at once, Next-
Generation Sequencing (NGS) has revolutionized the way human genetic diseases are 
investigated and diagnosed. Thanks to NGS and dedicated bioinformatics pipelines, both 
research and molecular diagnosis can be performed in a truly unsupervised way, by assessing 
thousands of DNA variants over entire genomes. However, this wealth of information is also 
a confounding factor when single events determining monogenic conditions are sought. 
Specifically, in Mendelian diseases only one or two pathogenic mutations must be precisely 
identified among the myriad of innocuous variants that are naturally present in the human 
genome, roughly reducing NGS-based analyses to the recognition of one true positive (the 
actual mutation) from many false positives (benign DNA changes). The genome of a single 
individual typically carries 20,000 exonic variants, including ~400 good-quality, 
nonsynonymous, and rare DNA changes.1,2 In recessive conditions, two of such variants have 
forcibly to be present in the same gene to cause disease, reducing the number of candidate 
genes associated with the pathology to only 5-10, genome-wide.1,3,4 In contrast, any gene 
harboring one of these 400 variants in a heterozygous state represents potentially a gene 
associated with a dominant disorder, making it difficult to identify the cause of this class of 
genetic conditions (Figure 1A). As a consequence, NGS-based studies appear to be almost 
10-fold more efficient in detecting novel genes linked to recessive disorders as compared to 
dominant ones.5 Prioritization of rare alleles as a function of their pathogenic potential at the 
heterozygous state represents therefore a crucial problem in solving novel dominant cases.  
Several in silico tools have been developed to predict the damaging effect of DNA 
changes.6,7 Yet, most of these methods focus on the deleteriousness of such variants on 
protein structure and/or function, rather than on making a distinction between mutations that 
are dominant or recessive. Other approaches predict haploinsufficiency of genes in the human 
genome.8-11 These methods provide a partial solution to this problem, since dominant variants 
can produce a phenotype not only by haploinsufficiency, but also by gain-of-function or 
dominant negative behavior.12 
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Here we propose an alternative approach, based on the scoring of features that 
distinguish genes associated with autosomal dominant (AD genes) vs. autosomal recessive 
(AR genes) disorders, rather than on properties that are specific to a given DNA variant. To 
this end, we developed a predictive tool, called DOMINO, based on Linear Discriminant 
Analysis (LDA), trained on a set of genes with known inheritance mode and over a series of 
specific features, and validated with an independent group of genes. 
We first collected a list of genes from different sources: hOMIM, a manually curated 
subset of OMIM13 (275 entries); RetNet, containing all genes involved in retinal degenerations 
and characterized by a high degree of genetic heterogeneity (99 entries); the Nosology of 
genetic skeletal diseases,14 listing genes linked to skeletal disorders (193 entries); and finally 
the full list of newly-discovered genes associated with Mendelian disorders published from 
2009 to 2015 in the American Journal of Human Genetics (418 entries). To ensure quality, we 
manually curated these sources by discarding (i) all genes having both AD and AR inheritance, 
(ii) genes directly linked to cancer, (iii) genes carrying mutations that were not reported in the 
literature in more than one pedigree, and (iv) genes associated with non-clinical phenotypes 
(Supplemental Methods and Table S1). We also removed all non-autosomal loci, as molecular 
evolution acts differently on autosomal vs. X-linked genes.15 This process resulted in the 
selection of 985 genes: 291 associated with AD phenotypes, and 694 with AR phenotypes, 
which were used as the “training set”. 
To provide the highest a priori discrimination power to our tool, we used a wide range 
of features obtained from various databases and covering most of the attributes that genes 
can have, including general genetic, evolutionary, interactional and functional information 
(Supplemental Methods and Table S2). Of the 700 different gene-specific features that could 
be extracted initially, 432 resulted to be available for protein-coding genes and allowed reliable 
scoring. These features were then filtered based on their significant differences between AD 
and AR genes of the training set (Supplemental Methods), producing in the end 308 usable 
features. 
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An LDA-based algorithm was then chosen to allow machine-learning from the training 
set of genes, not only because of its recognized performance as a statistical method, but also 
to ensure the precise identification of the relevant features selected by the final model, allowing 
potentially to gain information on their biological relevance in the context of AD vs. AR genes. 
To build a robust scoring system and to prevent over-fitting the training data, we devised an 
iterative process, able to identify the most discriminant features (Figure 1B, Supplemental 
Methods). We first chose the one feature individually producing the highest area under the 
curve (AUC) from the receiver operating characteristic (ROC) function. Then, we iteratively 
tried to remove, replace or add features with specific criteria of acceptance (increase or 
decrease of the AUC, Figure 1C). Each time a change was accepted, 10x 10-fold cross-
validation16 was applied to the training set, to generate a “testing set” (Figure 1C). We let the 
algorithm run for 40 iterations and selected as best model the one for which there was an 
optimal AUC for the training and testing sets (Figure 1D). In other words, we selected the least 
complex model among those displaying similar AUC values. In our case, the best model was 
the one tested at the 14th iteration, composed of 8 features (Figure 1D) and displaying AUCs 
of 0.912 and 0.908 for the training and testing sets, respectively (Figure 1E). Starting from the 
15th iteration, we also observed a limited improvement of the testing set and a decreased 
performance for the validation set, clearly indicating over-fitting of the model on the training 
set, in support of this initial threshold selection. For each gene, in decreasing order of 
importance, the selected features were: (1) the number of interactions with AD genes of the 
training set from the combined score of STRING (a database regrouping functional protein 
association networks from various sources), with a confidence >500 and a maximum of 8 
interactions,17 (2) pRec (probability to be intolerant to homozygous but not heterozygous loss-
of-function variants) as extracted from ExAC,18 (3) the number of interactions with AD genes 
of the training set from the experimental score of STRING, with a confidence >400 and a 
maximum of 3 interactions,17 (4) the missense z-score from ExAC (intolerance to 
missenses),18 (5) the average PhyloP score for mammals across the transcriptional start site 
(TSS) (+/- 500 bp from the actual site),19 (6) the number of interactions with AD genes of the 
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training set using the text-mining score of STRING, with a confidence >300 and a maximum 
of 3 interactors,17 (7) the ratio between the number of donor site variants and synonymous 
variants present in ExAC,20 (8) a high mRNA half-life (>10h) in mouse embryonic stem cells21 
(Figure 1F, Figures S1). 
At the end of this process, a score was computed for each gene, based on the LDA 
model. To facilitate the interpretation of the results by the end user, we transformed this score 
in a probability value, P(AD), measuring the probability for a gene to carry dominant mutations 
(Figure 2A, and Supplemental Methods), and developed a web-based interface, enabling the 
interactive query of candidate genes and the scoring of their AD potential. As expected from 
the ROC curve (Figure 1E), most AD genes from the training set had a high P(AD), displaying 
the opposite trend when compared to AR genes (Figures 2B and 2C). At the maximal 
informedness point (LDA score = 0.225), computed by the Youden’s J equation (Jmax), the 
model had a specificity of 84.7% and a sensitivity of 80.4%. Interestingly, genes known to 
cause deleterious phenotypes by both dominant and recessive mechanisms, which we 
recovered from the pool of discarded genes from the training set and tested as new 
candidates, were scored either as AD or AR genes (Table S3). Specifically, out of 78 of such 
loci, 43 (55.1%) had a LDA score>0.225, whereas the rest had P(AD)s comparable to those 
of genes associated with recessive disorders (Figure S2A), indicating the absence of an 
artefactual bias created by the model. 
As a “validation set”, we used 99 genes with Mendelian mutations (26 AD genes and 
73 AR genes) that we extracted from papers published from January 2016 to March 2017 in 
The American Journal of Human Genetics and in Nature Genetics, to mimic the discovery of 
newly-reported genes and confirm the absence of a potential bias towards well-studied and 
annotated genes, composing the bulk of the training set (Table S4). For the validation set, 
DOMINO predicted AD association with an AUC of 0.920 (Figures 1D and 1E) and specificity 
and sensitivity of 88.5% and 78.1% at Jmax, respectively (Table S4, Figures 2D and 2E). 
Specifically, 23 out of the 26 AD genes were correctly identified, confirming the reproducibility 
of the data obtained with the training set. For the remaining three dominant genes that were 
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not recognized as such, namely: OVOL2 [MIM: 616441], KLHL24 [MIM: 611295], and 
SAMD9L [MIM: 611170], we noted unconventional mechanisms of pathogenicity. OVOL2 
contains variants in the non-coding promoter region that results in a hyperactive promoter,22 
while KLHL24 has a start-loss DNA change resulting in the use of a downstream alternative 
initiation site.23 The mechanisms of pathogenesis for SAMD9L are also rather unusual for a 
Mendelian condition, and are characterized by particular chromosomal rearrangements.24 
AD mutations can cause pathological phenotypes via different mechanisms, such as 
gain-of-function or haploinsufficiency. To examine the effectiveness of DOMINO in these two 
different cases, we evaluated AD genes from the training set as a function of the type of 
causative mutations they harbor. We reasoned that genes carrying exclusively pathogenic 
missenses (N=107) would mainly cause disease by gain-of-function mechanisms, whereas 
those containing only truncating variants (N=40) would be compatible with a haploinsufficient 
model of pathogenesis (genes carrying both types of variants were excluded, Table S5). 
Scores for the two groups were not statistically different (Figures S2B and S2C), with average 
P(AD) values of 0.66 and 0.74, respectively (p=0.42, by Wilcoxon rank sum test with continuity 
correction). Therefore, in contrast to current tools, DOMINO’s effectiveness is not affected by 
the presence of specific mutations that a given gene may harbor, being a true predictor of AD 
features regardless of their mode of pathogenesis. 
The performance of our model was also assessed by scoring the probability of being 
dominant for well-known false-positives for rare conditions in genome-wide screens,25 such 
as genes encoding mucins, taste and olfactory receptors, etc. Out of 436 genes from this set, 
only 4 had LDA scores higher than Jmax (Table S6, Figure 2F). 
To assess the behavior of DOMINO on real sets of exome / genome data, we tested it 
on genotypes from denovo-db, a database of de novo variants identified by NGS,26 from which 
we extracted data from individuals with intellectual disability (ID) (N=1,010) or with epilepsy 
(N=532). Following a stringent filtering on allelic frequency (never seen before in ExAC and 
ESP),20 predicted effect on protein (nonsense, frameshift, missense) or on splicing (disruption 
of splicing sites), we selected all genes with at least two variants in different individuals (N=82 
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for intellectual disabilities and N=19 for epilepsy, Tables S7 and S8). By virtue of their 
heterozygous de novo inheritance (i.e. dominant in following generations), their presence in 
the same gene in more than one person, and of strict filtering procedures, all these DNA 
changes likely represent pathogenic mutations, and therefore all genes harboring them 
represent true AD genes detected by real NGS experiments. We then ranked all autosomal 
genes from the human genome according to their P(AD) and retained those for which P(AD) 
was ≥0.95, i.e. all genes that were predicted to be associated to dominant conditions with high 
confidence. Subsequently, we assessed the enrichment of genes with P(AD)≥0.95 in these 
two groups of diseases within all human autosomal genes with P(AD)≥0.95, by a 
hypergeometric test. We found that genes with at least two de novo variants from both the ID 
and epilepsy cohorts were significantly enriched for high P(AD) genes, with associated p-
values of 1.8x10-35 (enrichment score=18.9) and 9.6x10-14 (enrichment score=43.1), 
respectively (Figure 3). 
Remarkably, for cases with epilepsy, all 15 genes with at least two variants in different 
individuals and with high P(AD) were already known to be associated with dominant forms of 
the disease (4 were present in the training set). For ID, 39 out of 51 bona fide genes with high 
P(AD) were also already associated with AD forms of the diseases and allied conditions in 
OMIM (11 were present in the training set). Among the 12 remaining genes, three were 
previously predicted to be linked to this disorder by a in silico analyses,27 whereas the other 9 
represent excellent intellectual disability candidate genes that we propose for validation by 
forthcoming studies (Table 1). In more general terms, genes with high P(AD) genome-wide 
represent therefore either genes that were already identified to be associated with dominant 
conditions, or excellent new candidate genes for known or novel AD conditions. For instance, 
among the top 20 genes with highest P(AD), 10 were previously found to carry mutations for 
dominant disorders, while the remainder were not associated with any condition, and may be 
considered in the future for disease association with very high confidence (Table 2). 
Finally, we took advantage of the LDA approach, allowing a transparent assessment 
of the features selected by the model, to gain possible insights on the general properties of 
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AD vs. AR genes. Interestingly, the STRING components, accounting globally for the 47.5% 
of the weight of the model, are strong determinants of dominance, implying that organization 
in networks is seemingly rather important for AD genes/proteins. Moreover, among the many 
parameters measuring evolutionary pressure and conservation across species, only the 
PhyloP score at the TSS was retained (11.4% of the weight), while more classical scores, 
such as for instance the dN/dS ratio,28 appeared to be less relevant and were not included in 
the final model. Sequence-based features were nonetheless significant and have been 
retained in DOMINO, accounting for 37.8% of the weight. Their significance seems to be 
related to the global variation landscape in the human population, as identified in the ExAC 
project.20 Another intriguing result emerging from the selection of features is the fact that few 
AD genes have a long mRNA half-life. This finding could possibly be related to the observation 
that stable transcripts are enriched for mRNA encoding enzymes,21 which are usually 
associated with AR conditions. Also, our analysis of NGS data from individuals with intellectual 
disability or epilepsy showed that DOMINO has relevant predictive power for identifying genes 
that have not yet been studied or not yet found to carry pathogenic mutations. 
In conclusion, DOMINO allows for an efficient prioritization of candidate genes for 
autosomal dominant Mendelian conditions, independently from the mutational events that a 
given gene may carry. Therefore, it can be used in combination with other predictors focusing 
on deleteriousness of DNA variants to reduce the number of false positives in mutational 
screens. In addition, the flexibility and modularity of the machine learning system enables the 
incorporation, at every update, of new informative features as they may emerge from future 
studies, making DOMINO a constantly evolving tool with progressively improving 
performances. 
 
SUPPLEMENTAL METHODS: 
Supplemental methods, including details on data collection, gene features, and 
properties of the algorithm are provided on the DOMINO main web site 
(https://wwwfbm.unil.ch/domino/).  
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Legends to figures 
 
Figure 1. Rationale and general design of DOMINO 
(A) A typical exome analysis identifies 20,000 variants, when compared to the human 
reference genome. After filtering by rarity in the general population (minor allele frequency, or 
MAF, <1%) and by functional impact of each variant, approximately 400 DNA changes remain. 
These impact 300-400 genes, heterozygously (red dots), and 5-10 genes when they are 
present as homozygous or compound heterozygous variants (blue dots). 
(B) Workflow of DOMINO methodology, showing the different steps of gene selection, 
annotation, and scoring. 
(C) Details of the LDA algorithm. Relevant features are first preselected and then removed, 
replaced or added iteratively to the model, with specific acceptance criteria. 10X 10-fold cross-
validation is performed at each step. 
(D) Performance of the model as a function of the iterations performed. AUCs of the training, 
testing and validation sets, as well as the number of features at each iteration are shown. The 
cut-off value retained corresponded to the 14th iteration and a set of 8 features. The model 
converges starting from the 36th iteration. 
(E) ROC curves for the complete training, testing and validation sets, displaying AUC values 
of 0.912, 0.908 and 0.920, respectively. 
(F) Features composing the selected model. Average values for AD and AR genes of the 
training set are shown, along with their relative weight. Units are as follows: for STRING 
entries, number of interactions;17 for ExAC-pREC, probability of being intolerant to 
homozygous but not heterozygous loss-of-function variants;18 for ExAC-missense z-score, 
value with respect to a distribution of expected number of missenses;18 PhyloP, average 
PhyloP score with respect to a 1,000-bp window centered on the TSS;19 ExAC-don./syn., 
number of variants at the donor splicing site, normalized to the number of synonymous 
variants in the coding sequence;20 mRNA half-life, 0 if ≤ 10 hrs or 1 if > 10 hrs.21 
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Figure 2. Distributions of LDA scores and probabilities of being dominant, P(AD), for 
genes in the training and validation sets.  
(A) Density plots of LDA score for AD (red) and AR (blue) genes of the training set. Continuous 
lines refer to raw values, whereas dashed lines to their normal approximations. 
(B-F) Histograms of P(AD) for (B) AD genes of the training set, (C) AR genes of the training 
set, (D) AD genes of the validation set, (E) AR genes of the validation set, (F) Genes known 
to behave as false positives in NGS experiments, containing rare, non-pathogenic variants. 
 
Figure 3. Distributions of P(AD) for genes with at least two de novo mutations in 
different individuals with intellectual disability or epilepsy.  
Histograms of P(AD) for (A) 82 genes carrying de novo mutations in 1,010 individuals with 
intellectual disability or (B) 19 genes carrying de novo mutations in 532 individuals with 
epilepsy, as extracted from denovo-db. 
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Table 1. Candidate genes for intellectual disability, as predicted by DOMINO and 
recurrent de novo mutations 
 
 
    
Gene name Protein name P(AD) Function 
    
    
AGO2 
[MIM:606229] 
Argonaute 2 0.999989 Catalytic component of the RNA-induced 
silencing complex (RISC) 
CACNA1E 
[MIM:601013] 
Calcium Voltage-
Gated Channel, 
Subunit Alpha1 
E 
0.995065 Calcium channels containing alpha-1E subunit. It 
could be involved in the modulation of firing 
patterns of neurons 
CHD3 
[MIM:602120] 
Chromodomain 
Helicase DNA 
Binding Protein 
3 
0.999901 Component of the histone deacetylase NuRD 
complex, participating in the remodelling of 
chromatin 
FBXO11 
[MIM:607871] 
F-Box Protein 11 0.973952 Part of a the SCF E3 ubiquitin-protein ligase 
complex, mediating protein ubiquitination and 
degradation 
GRIA1 
[MIM:138248] 
Glutamate 
Ionotropic 
Receptor, AMPA 
Type, Subunit 1 
0.980767 Receptor for glutamate, mediating fast excitatory 
synaptic transmission in the central nervous 
system 
KDM2B 
[MIM:609078] 
Lysine 
Demethylase 2B 
0.989312 Histone demethylase that demethylates Lys-4 
and Lys-36 of histone H3 
LRP1 
[MIM:107770] 
LDL Receptor 
Related Protein 
1 
0.999963 Endocytic receptor involved in endocytosis and in 
phagocytosis of apoptotic cells 
PPP2CA 
[MIM:176915] 
Protein 
Phosphatase 2, 
Catalytic Subunit 
Alpha 
0.999621 Protein phosphatase 2A is one of the four major 
Ser/Thr phosphatases, implicated in the negative 
control of cell growth and division. 
TCF7L2 
[MIM:602228] 
Transcription 
Factor 7 Like 2 
0.999903 Participates in the Wnt signaling pathway and 
modulates MYC expression 
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Table 2. Top 20 AD genes, as predicted by DOMINO 
 
 
    
Gene P(AD) In training set Main OMIM description 
    
    
SF3B1 [MIM:605590] 0.999999 No Myelodysplastic syndrome, 
somatic/dominant [MIM:614286] 
CSNK2A1 [MIM:115440] 0.999998 No Okur-Chung syndrome, autosomal 
dominant [MIM:617062] 
LHX2 [MIM:603759] 0.999998 No Unassigned 
DACH1 [MIM:603803] 0.999998 No Unassigned 
PAX6 [MIM:607108] 0.999998 Yes, AD Aniridia, autosomal dominant 
[MIM:106210] 
PRPF8 [MIM:607300] 0.999996 No Retinitis pigmentosa, autosomal dominant 
[MIM:600059] 
ATP2B1 [MIM:108731] 0.999996 No Unassigned 
DYNC1H1 
[MIM:600112] 
0.999996 Yes, AD Charcot-Marie-Tooth disease, axonal, 
autosomal dominant [MIM:614228] 
PIK3CA [MIM:171834] 0.999995 Yes, AD Cowden syndrome 5, autosomal dominant 
[MIM:615108] 
PTEN [MIM:601728] 0.999995 No Bannayan-Riley-Ruvalcaba syndrome, 
autosomal dominant [MIM:153480] 
TBL1XR1 [MIM:608628] 0.999995 No Intellectual disability, autosomal dominant 
[MIM:616944] 
HNRNPR [MIM:607201] 0.999994 No Unassigned 
TOP2B [MIM:126431] 0.999994 No Unassigned 
GSK3B [MIM:605004] 0.999993 No Unassigned 
CDK8 [MIM:603184] 0.999992 No Unassigned 
XPO1 [MIM:602559] 0.999992 No Unassigned 
SREBF1 [MIM:184756] 0.999992 No Unassigned 
PIAS1 [MIM:603566] 0.999991 No Unassigned 
NR2F2 [MIM:107773] 0.999991 Yes, AD Congenital heart defects, autosomal 
dominant [MIM:615779] 
BCL11B [MIM:606558] 0.999990 No Immunodeficiency 49, autosomal dominant 
[MIM:617237] 
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Web Resources 
 
DOMINO (web interface and Supplemental Methods): https://wwwfbm.unil.ch/domino/ 
ExAC : http://exac.broadinstitute.org/ 
Exome Variant Server (ESP) : https://evs.gs.washington.edu/EVS/ 
RetNet : https://sph.uth.edu/retnet/ 
STRING: https://string-db.org/ 
Online Mendelian Inheritance in Man (OMIM): http://www.omim.org 
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